NDA 050767/S-018
NDA 050680/S-019

SUPPLEMENT APPROVAL

Pfizer, Inc.
Attention: Mikhail Abarshalin
Director, Pfizer Global Regulatory Affairs
235 East 42nd Street
New York, NY 10017-7555

Dear Mr. Abarshalin:

Please refer to your supplemental new drug applications (sNDA) dated and received August 16, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

NDA AND SUPPLEMENT NUMBERS:	NDA 050767/S-018 NDA 050680/S-019
PRODUCT NAMES:	[NDA 050767] Cleocin Vaginal Ovules (clindamycin phosphate vaginal suppositories) [NDA 050680] Cleocin (clindamycin phosphate vaginal cream, USP)

These "Changes Being Effected" sNDAs provide for revisions to the prescribing information (PI), including the **ADVERSE REACTIONS** section to add/modify information as it relates to acute kidney injury and nephrotoxicity and drug reaction with eosinophilia and systemic symptoms (DRESS). We note minor editorial revisions were also made throughout the PI.

APPROVAL & LABELING

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

FDA.gov.[1] Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.[2]

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for these NDAs, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in these supplemental applications, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

[1] http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
[2] We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

If you have questions, call Sheel Shah, Pharm D, Regulatory Project Manager, at 240-402-3968.

Sincerely,

{See appended electronic signature page}

Dmitri Iarikov, MD, PhD
Deputy Director
Division of Anti-Infectives
Office of Infectious Diseases
Center for Drug Evaluation and Research

ENCLOSURE:

- Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

DMITRI IARIKOV
05/17/2022 09:44:20 AM